Clinical Trial Update: A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating camrelizumab with capecitabine and oxaliplatin, followed by camrelizumab with apatinib, in advanced/metastatic gastric cancer or gastro…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Apatinib Mesylate (apatinib)
• Camrelizumab (camrelizumab)
• Capecitabine (capecitabine)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Gastric Cancer, GastroEsophageal Cancer | Phase 3 | Status: COMPLETED